Skip to main content

Table 3 Overview of anti-calcitonin-gene related (CGRP) (receptor) peptide monoclonal antibodies in order by target and alphabetical

From: Therapeutic novelties in migraine: new drugs, new hope?

Drug Target Administration Interval between administrations Status
Erenumab (AMG-334) Receptor Subcutaneous injection 4 weeks FDA approved; phase III clinical trials
Eptinezumab (ALD403) Ligand Intravenous infusion 12 weeks Phase III clinical trials
Fremanezumab (TEV-48125) Ligand Subcutaneous injection 4 or 12 weeks FDA approved; phase III clinical trials
Galcanezumab (LY2951742) Ligand Subcutaneous injection 4 weeks FDA approved; phase III clinical trials
  1. *FDA: The US Food and Drug Administration
\